Abstract Number: 1785 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Relative Factors of Infections in Southern Chinese Patients with Systemic Lupus Erythematosus
Background/Purpose: To determine the clinical characteristics and to identify relative factors of infection in patients with Systemic Lupus Erythematosus, to provide a data for making…Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…Abstract Number: 1787 • 2015 ACR/ARHP Annual Meeting
Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, compared to…Abstract Number: 1788 • 2015 ACR/ARHP Annual Meeting
Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Background/Purpose: Risk of atherosclerotic cardiovascular disease (CVD) is significantly enhanced in systemic lupus erythematosus (SLE) compared to age and gender matched controls. While this risk…Abstract Number: 1789 • 2015 ACR/ARHP Annual Meeting
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Background/Purpose: SLE is associated with a significantly increased risk of infection. Both disease activity and the medications required to control disease are contributory factors. Rituximab…Abstract Number: 1790 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Suppresses Humoral Response to Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Background/Purpose: To determine the efficacy of pneumococcal polysaccharide vaccine (PPV-23) in patients on mycophenolate mofetil (MMF) therapy and compare efficacy to other DMARDS.Methods: In…Abstract Number: 1791 • 2015 ACR/ARHP Annual Meeting
Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study
Background/Purpose: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently used as an adjuvant treatment in lupus nephritis (LN) patients for the…Abstract Number: 1792 • 2015 ACR/ARHP Annual Meeting
Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review
Background/Purpose: Premature coronary heart disease (CHD) represents a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE). Several studies have been conducted to…Abstract Number: 1793 • 2015 ACR/ARHP Annual Meeting
Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus
Background/Purpose: Elevated muscle enzymes in the course of systemic lupus erythematosus (SLE) usually represent active myositis or drug-related toxicity. Lipid-lowering agents and, less frequently, antimalarials…Abstract Number: 1794 • 2015 ACR/ARHP Annual Meeting
Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients
Background/Purpose: We have observed a decline in rates of cardiovascular events in systemic lupus erythamatosus (SLE) pateints in our clinic. In this work presented below,…Abstract Number: 1795 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
Background/Purpose: Tacrolimus (Tac) is an immunosuppressive macrolide that blocks T cell activation by specifically inhibiting calcineurin. Some randomized controlled studies have shown that TAC is an…Abstract Number: 1796 • 2015 ACR/ARHP Annual Meeting
Progression of Atherosclerosis Might be Prevented By Decrease of Serum Resistin Level after Glucocorticoid Therapy in Patients with Systemic Autoimmune Disease
Background/Purpose: Development of atherosclerosis is accelerated in patients with systemic autoimmune diseases. However, underlying mechanisms of accelerated atherosclerosis remains unknown, and the impact of pharmacotherapies…Abstract Number: 1797 • 2015 ACR/ARHP Annual Meeting
Insulin Resistance Is Not Associated with Increased Risk of Subclinical Atheromatosis in Patients with Systemic Lupus Erythematosus from Northern Spain
Background/Purpose: Metabolic syndrome is a recently defined clustering of cardiovascular risk (CV) factors associated with insulin resistance (IR) and an increased risk of CV disease.…Abstract Number: 1798 • 2015 ACR/ARHP Annual Meeting
Progression of Noncalcified and Calcified Coronary Plaque (by CT Angiography) in SLE
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. Coronary artery calcium (CAC) is a late…Abstract Number: 1799 • 2015 ACR/ARHP Annual Meeting
IgG Levels Correlate Inversely with Proteinuria Among Participants in the Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Trial, but Hypogammaglobulinemia Was Not Associated with an Increased Risk of Serious Infection
Background/Purpose: Hypogammaglobulinemia has been associated with serious infectious adverse events (SIAE) and may occur during immunosuppressive therapy for lupus nephritis (LN). It is possible that…
ACR Meeting Abstracts